Neuromyelitis Optica Spectrum Disorder: An Early Diagnosis to Prevent Blindness and Paraplegia

被引:0
|
作者
George, Minny [1 ]
Gantioque, Raymund [1 ]
机构
[1] Calif State Univ, Sch Nursing, 5151 State Univ Dr, Los Angeles, CA 90032 USA
来源
关键词
Devic's disease; monoclonal antibodies; neuromyelitis optica; neuromyelitis optica (NMO) antibody AQP4-IgG; neuromyelitis optica spectrum disorder; optic neuritis; transverse myelitis; MULTICENTER; EFFICACY; SAFETY; TRIAL;
D O I
10.1016/j.nurpra.2023.104654
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
Neuromyelitis optica spectrum disorder (NMOSD), also referred to as Devic's disease, is a rare autoimmune disease of the central nervous system that primarily affects both the optic nerve (optic neuritis) and the spinal cord (myelitis). Patients presenting solely with optic neuritis or transverse myelitis can make diagnosis difficult. If left untreated, it may result in blindness and paralysis. Early and accurate diagnosis is crucial for treating and preventing further NMOSD attacks. This article describes the case of a previously healthy patient who presented with NMOSD. In addition, the clinical presentation, diagnostics, and treatment methods are discussed.& COPY; 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:4
相关论文
共 50 条
  • [41] Frequency of comorbidities in neuromyelitis optica spectrum disorder
    Barzegar, M.
    Mirmosayyeb, O.
    Nehzat, N.
    Vaheb, S.
    Shaygannejad, V.
    Asgari, N.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 460 - 460
  • [42] Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
    Yamamura, Takashi
    Kleiter, Ingo
    Fujihara, Kazuo
    Palace, Jacqueline
    Greenberg, Benjamin
    Zakrzewska-Pniewska, Beata
    Patti, Francesco
    Tsai, Ching-Piao
    Saiz, Albert
    Yamazaki, Hayato
    Kawata, Yuichi
    Wright, Padraig
    De Seze, Jerome
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (22): : 2114 - 2124
  • [43] Depression in patients with neuromyelitis optica spectrum disorder
    Seok, J. M.
    Choi, M.
    Kim, Y. S.
    Cho, E. B.
    Lee, H. L.
    Kang, S. -Y.
    Lee, K. H.
    Kim, B. J.
    Min, J. -H.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 94 - 94
  • [44] Hypogeusia as a symptom of neuromyelitis optica spectrum disorder
    Iones, Anna
    Howard, Jonathan
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 1548 - 1549
  • [45] Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Tina Nie
    Hannah A. Blair
    CNS Drugs, 2022, 36 : 1133 - 1141
  • [46] Choreoathetosis in a patient with neuromyelitis optica spectrum disorder
    Sugeno, Naoto
    Izumi, Rumiko
    Kato, Kazuhiro
    Nakashima, Ichiro
    Takeda, Atsushi
    Aoki, Masashi
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2013, 1 (04): : 154 - 156
  • [47] Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Nie, Tina
    Blair, Hannah A.
    CNS DRUGS, 2022, 36 (10) : 1133 - 1141
  • [48] Response to "Epidemiology of neuromyelitis optica spectrum disorder''
    Dale, G. H.
    Bacher Svendsen, K.
    Gjelstrup, M. C.
    Christensen, T.
    Houen, G.
    Nielsen, E.
    Bek, T.
    Petersen, T.
    ACTA NEUROLOGICA SCANDINAVICA, 2018, 137 (06): : 628 - 629
  • [49] Neuromyelitis optica spectrum disorder and active tuberculosis
    Grieve, James Kerr
    Day, Scott
    Connell, David
    O'Riordan, Jonathan
    BMJ CASE REPORTS, 2020, 13 (01)
  • [50] Eculizumab in the treatment of neuromyelitis optica spectrum disorder
    Nabizadeh, Fardin
    Moghadasi, Abdorreza Naser
    CURRENT JOURNAL OF NEUROLOGY, 2023, 22 (02): : 140 - 143